Dr. Prashant Vaishnava, MD

Dr. Vaishnava practices at Trustees of Columbia University in the City of NY in New York, New York.

Dr. Vaishnava's NPI, 1942351465, was assigned on January 12, 2007. Dr. Vaishnava graduated from Michigan State University College of Human Medicine in 2005. Dr. Vaishnava holds New York license 253971.

Dr. Vaishnava's primary practice is Trustees of Columbia University in the City of NY, at 630 W 168th St, New York, NY 10032 in New York County. The practice phone is (212) 342-5155.

Dr. Vaishnava's primary practice is Trustees of Columbia University in the City of NY in New York, New York. Dr. Vaishnava is also affiliated with NYC Health + Hospitals/Harlem. The medical group on file is Mount Sinai Institute for Liver Medicine. Dmand AI also links Dr. Vaishnava to 4 more hospitals, 8 medical groups, 7 group practices and clinics and 1 rural health clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Vaishnava practices, 13 sites in all. Vendor and product names are available with a free account.

Cardiovascular disease is Dr. Vaishnava's primary specialty in the NPI Registry, under taxonomy code 207RC0000X. Dmand AI has Dr. Vaishnava's licenses on file in 3 states: New York, Massachusetts and Michigan.

CMS data shows 1,119 Medicare services from Dr. Vaishnava across 12 procedure codes in 2024, for 737 Medicare patients. Medicare paid $47,833 for them.

CMS counts 737 Medicare patients who saw Dr. Vaishnava in 2024. The largest group is 65 to 74, with 284 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 21% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Vaishnava's median patient age at 74, with 54% women.

In 2024, Dr. Vaishnava wrote 921 Medicare Part D claims for 125 patients. 78% of them were for generic drugs. CMS names the drug for 726 of them, across 22 drugs with 11 or more claims each, at $170,601 in total drug cost. In 2023, CMS named 435 claims across 17 drugs.

Dr. Vaishnava accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 31 papers to Dr. Vaishnava, published from 2011 to 2020. 2011 was the busiest year, with 4. The most frequent topics are Myocardial Infarction, Postoperative Complications and Surgical Procedures, Operative. Dr. Vaishnava has published most often in Ann Intern Med. Dr. Vaishnava's most frequent co-authors are Valentin D. Fuster, MD, Martin E. Goldman, MD and Anelechi Chinedu Anyanwu, MD.

CMS Open Payments shows 38 general payments to Dr. Vaishnava from 16 drug and device companies from 2020 to 2025. Food and beverage make up the largest share, 89% of the total. Boehringer Ingelheim Pharmaceuticals, Inc. paid the most, $341.

Dr. Vaishnava graduated from Michigan State University College of Human Medicine in 2005.